Letter to the Editor

Allergic and photoallergic contact dermatitis to Olaquindox in a pig breeder with prolonged photosensitivity

H. Belhadjali1, M. C. Marguery1, F. Journe1, F. Giordano-Labadie1, H. Lefebvre2, J. Bazex1

1Department of Dermatology, Purpan’s Hospital, and 2National Veterinary School, Toulouse, France

To the editor,

Olaquindox is an allergen and photoallergen specifically affecting pig breeders. Only a few cases of allergic and photoallergic contact dermatitis have been reported since 1985 (1–5). We report a new case which stresses the importance of Olaquindox as an allergen and photoallergen capable of inducing prolonged photosensitivity.

A 53-year-old man presented in March 1999 with a photodistributed eczema on the face (sparing eyelids), neck and backs of the hands and fingers. He had been taking Rilmenidine (Hyperium®) and Diltiazem (Monotildiem®) for 4 years, Pravastatin (Elisor®) for 1 year withdrawn in March 1999. The patient was atopic. He had also worked as a pig breeder for 10 years and used azaperone (Stresnil®), a sedative drug for pigs, oxytetracycline (Duphacycline®) and Olaquindox, an antibiotic molecule which is added to the pigs food to avoid enteritis at the time of weaning. Olaquindox was included in a vitamin and mineral complex presented in powder form. The photobiological testing was performed with two sources of light: polychromatic irradiation (UVB, UVA, visible) provided by a device consisting of a xenon lamp and a metal halide lamp (Dermolum UM-W®, Müller, Germany) filtered with a Schott WG 305–1 mm filter, dosimetry being performed with a thermopile giving the total irradiance and by a high pressure UVA lamp (UVA-700®, Waldmann, France), emitting in the UVA1 range (340–400 nm) with an incorporated dosimeter. The polychromatic minimal erythema dose was 720 mJ/cm² (normal $500$ mJ/cm²). The simple UVA phototest (13 J/cm²) was negative at 24 h. The patch and photopatch tests were performed with the standard series of the French Society of Photodermatology (28 photoallergens), one series of pesticides and three drugs, namely Elisor®, Hyperium® and Monotildiem® (the tablets were crushed and then diluted in 10% water and 10% vaseline). Patch tests were performed in triplicate and the patches removed after 24 h in two series. One series was irradiated with 5J/cm² of UVA, the second series with a suberythemal dose of polychromatic radiation (0.75 MED); the third non-irradiated series served as the control. The patch tests and photopatch tests showed a contact allergy to fragrance mix, balsam of Peru, Captan and Folpet, as appearing irrelevant to this photodistributed eczema. The drug photopatch tests remained negative. Two months later and

Fig. 1: Olaquindox UVA photopatch tests at 48 h

Fig. 2: Structural formula of Olaquindox
Table 1. Results of photopatch tests

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>UVA, 53 J/cm²</th>
<th>UVB, 3/4 MED</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>48 h</td>
<td>72 h</td>
<td>24 h</td>
</tr>
<tr>
<td>Olaquindox</td>
<td>–</td>
<td>+/–</td>
<td>+/–</td>
</tr>
<tr>
<td>0.1% water</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>0.5% water</td>
<td>+†</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>0.5% vaseline*</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>10% vaseline*</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Stresnil® (azaperone)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1% water</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>0.4% water</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Duphacycline® (oxytetracycline)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>20% water</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

†† to †+ as recommended by the International Contact Dermatitis Research Group

8 days after the removal of Olaquindox, there was still a photodistributed eczema, the polychromatic MED was decreased to 259 mJ/cm² and the UVA MED was reduced to 5 J/cm². Patch tests and photopatch tests with Olaquindox showed a contact and photocontact allergy in UVA and UVB (Table 1, Fig. 1). Four months after withdrawal of the Olaquindox, the clinical symptoms persisted with a photodistributed eczema and photosensitivity. The polychromatic MED (1849 mJ/cm²) and the UV A MED (>13 J/cm²) were now normal. In December 2000, the patient was recalled and reported a photosensitivity with pruritus, erythema and papules occurring on the face after each short UV exposure. Thus, the evolution showed a prolonged photosensitivity more than a year and a half after withdrawal of the Olaquindox.

Structurally, Olaquindox presents two benzene rings, with alternating simple and double bonds (4) leading to its photosensitizing properties (Fig. 2). In 1996 Schauder et al. (4) reported 15 cases of allergic (four cases) and photoallergic contact dermatitis (11 cases) to Olaquindox. The time delay between the first Olaquindox contact and the onset of photosensitivity varied between 1 month to several years (7–11 years) somewhat like the 10 years seen in our case. The evolution of the eruption showed a transient light reaction in four cases and persistent light eruption or chronic actinic dermatitis in 10 cases. In our case, the evolution showed a prolonged photosensitivity more than a year and a half after withdrawal of the Olaquindox. Since 1st September 1999, however, Olaquindox has been removed from the market in all European Community countries according to the Official Journal of the European Community, but this is not the case in other countries.

We recommend the practice of patch and photopatch tests to Olaquindox in pig breeders with photosensitivity, even in the European Community countries, given the high frequency of transient light reaction and chronic actinic dermatitis with this particular allergen. Furthermore, Olaquindox should, in due course, be withdrawn world-wide because of the potential persistent nature of Olaquindox contact photoallergy.

References

Corresponding author:
M. C. Marguery
Department of Dermatology
CHU-Purpan-Toulouse
Place du Dr Baylac
F-31059 Toulouse
France
Tel: +33 561 772 412
Fax: +33 561 777 672
e-mail: marguery.mc@chu-toulouse.fr